ArticleDrug delivery2020
Gefitinib loaded nanostructured lipid carriers: characterization, evaluation and anti-human colon cancer activity
Article in Drug delivery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 52 citations in OpenAlex.
- Advances in Nanostructured Lipid Carriers for Colorectal Cancer Treatment: A Comprehensive Review.Current drug delivery · 2026Review
- Liposomal Delivery Systems for Improved Delivery of Docetaxel Against Prostate Cancer.International journal of nanomedicine · 2026Review
- Enhancing anthocyanin stability via co-assembled nanoencapsulation with tripeptides by intermolecular interaction.Food chemistry: X · 2025Article
- Codelivery of Paclitaxel and Cannabidiol in Lipid Nanoparticles Enhances Cytotoxicity against Melanoma Cells.ACS omega · 2025Article
- Gefitinib induces apoptosis in Caco-2 cells via ER stress-mediated mitochondrial pathways and the IRE1α/JNK/p38 MAPK signaling axis.Medical oncology (Northwood, London, England) · 2025Article
- Unraveling the Pivotal Role of Nanovesicle Drug Delivery Systems in Colorectal Cancer: A New Paradigm in Therapeutics.Current pharmaceutical design · 2025Review
- Application of Metal-Organic Frameworks Nanoparticles in the Diagnosis and Treatment of Breast Cancer.International journal of nanomedicine · 2025Review
- Capecitabine-loaded NLC for Breast Cancer Treatment: Preparation, Characterization, andCurrent drug delivery · 2025Article
- Establishment of a novel microfluidic co-culture system for simultaneous analysis of multiple indicators of gefitinib sensitivity in colorectal cancer cells.Mikrochimica acta · 2024Article
- Targeting the Gut: A Systematic Review of Specific Drug Nanocarriers.Pharmaceutics · 2024Review
- Surface-Modified Biobased Polymeric Nanoparticles for Dual Delivery of Doxorubicin and Gefitinib in Glioma Cell Lines.ACS omega · 2023Article
- Enhanced Codelivery of Gefitinib and Azacitidine for Treatment of Metastatic-Resistant Lung Cancer Using Biodegradable Lipid Nanoparticles.Materials (Basel, Switzerland) · 2023Article
- Development of lactate-related gene signature and prediction of overall survival and chemosensitivity in patients with colorectal cancer.Cancer medicine · 2023Article
- Hepatoprotective Effect of Curcumin Nano-Lipid Carrier against Cypermethrin Toxicity by Countering the Oxidative, Inflammatory, and Apoptotic Changes in Wistar Rats.Molecules (Basel, Switzerland) · 2023Article
- Pentapeptide cRGDfK-Surface Engineered Nanostructured Lipid Carriers as an Efficient Tool for Targeted Delivery of Tyrosine Kinase Inhibitor for Battling Hepatocellular Carcinoma.International journal of nanomedicine · 2023Article
- Influence of Vegetable Oils on In Vitro Performance of Lutein-Loaded Lipid Carriers for Skin Delivery: Nanostructured Lipid Carriers vs. Nanoemulsions.Pharmaceutics · 2022Article
- Engineered Nanoscale Lipid-Based Formulation as Potential Enhancer of Gefitinib Lymphatic Delivery: Cytotoxicity and Apoptotic Studies Against the A549 Cell Line.AAPS PharmSciTech · 2022Article
- Cytotoxicity of Mahanimbine from Curry Leaves in Human Breast Cancer Cells (MCF-7) via Mitochondrial Apoptosis and Anti-Angiogenesis.Molecules (Basel, Switzerland) · 2022Article
- PEGylated SLN as a Promising Approach for Lymphatic Delivery of Gefitinib to Lung Cancer.International journal of nanomedicine · 2022Article
- Preparation, Characterization, and Anti-Cancer Activity of Nanostructured Lipid Carriers Containing Imatinib.Pharmaceutics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
NLC containing Gefitinib (NANOGEF) was prepared using stearic acid, sesame oil and surfactants (sodium lauryl sulfate and tween 80). NANOGEFs were evaluated for particle size, polydispersity index (PdI), zeta potential, entrapment efficiency (EE), stability, release studies and cytotoxicity studies (MTT assay). The optimized NANOGEF exhibited particle size of 74.06 ± 9.73 d.nm, PdI of 0.339 ± 0.029 and EE of 99.76 ± 0.015%. The TEM study revealed spherical shape of NANOGEF formulations. The slow and sustained release behavior was exhibited by all NANOGEFs. The effects of surfactants were observed not only on particle size but also on zeta potential, entrapment efficiency, stability and release studies. The MTT assay revealed 4.5 times increase in cytotoxicity for optimized NANOGEF (IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.